Reaction
Breast Neoplasm reporting signals
As of the last recalculation, Breast Neoplasm appears in 1,017 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 88.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 35 | 88.0 | 88.3 |
| Pertuzumab | 48 | 37.9 | 37.9 |
| Lapatinib | 26 | 35.2 | 35.2 |
| Ciclesonide | 19 | 29.1 | 29.1 |
| Trastuzumab | 74 | 23.7 | 23.7 |
| Ribociclib | 24 | 15.9 | 15.9 |
| Estrogens, Conjugated | 42 | 15.1 | 15.1 |
| Conjugated Estrogens | 41 | 15.0 | 15.0 |
| Goserelin | 9 | 13.8 | 13.8 |
| Letrozole Tablets | 31 | 13.6 | 13.6 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 15 | 13.2 | 13.2 |
| Anastrozole | 23 | 13.1 | 13.1 |
| Capecitabine | 46 | 10.7 | 10.7 |
| Docetaxel Anhydrous | 28 | 8.7 | 8.7 |
| Docetaxel | 28 | 8.7 | 8.7 |
| Paclitaxel (Aibumin-Bound) | 33 | 8.5 | 8.5 |
| Paclitaxel | 37 | 7.9 | 7.9 |
| Siponimod | 3 | 6.9 | 6.9 |
| Medroxyprogesterone Acetate | 14 | 5.8 | 5.8 |
| Benralizumab | 5 | 5.1 | 5.1 |